Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lunai Bioworks Inc.RENB · Entity 7981 | Director · Chief Executive Officer | February 13, 2024 | February 16, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lunai Bioworks Inc.
Report date February 13, 2024 · Filed February 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.95 · Expires 2028-02-28 | Direct | 0 |
Reported balance
After 2024-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-13 · Disposition to issuer · Disposed 7,563 · Balance 0 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F1: The option vested in three equal installments on February 28, 2019, February 28, 2020 and February 28, 2021. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2028-02-28 | Direct | 7,563 |
Reported balance
After 2024-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-13 · Grant · Acquired 7,563 · Balance 7,563 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $5.74 · Expires 2028-09-19 | Direct | 0 |
Reported balance
After 2024-02-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-13 · Disposition to issuer · Disposed 5,226 · Balance 0 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2028-09-19 | Direct | 5,226 |
Reported balance
After 2024-02-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-13 · Grant · Acquired 5,226 · Balance 5,226 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2028-11-21 | Direct | 0 |
Reported balance
After 2024-02-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-13 · Disposition to issuer · Disposed 300,000 · Balance 0 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2028-11-21 | Direct | 300,000 |
Reported balance
After 2024-02-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-13 · Grant · Acquired 300,000 · Balance 300,000 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2031-06-11 | Direct | 0 |
Reported balance
After 2024-02-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-02-13 · Disposition to issuer · Disposed 450,000 · Balance 0 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2031-06-11 | Direct | 450,000 |
Reported balance
After 2024-02-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-02-13 · Grant · Acquired 450,000 · Balance 450,000 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.57 · Expires 2031-07-19 | Direct | 0 |
Reported balance
After 2024-02-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-02-13 · Disposition to issuer · Disposed 2,000,000 · Balance 0 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F3: The option vested in two equal installments on July 1, 2022 and July 1, 2023. The remainder of the option vests on July 1, 2024. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2031-07-19 | Direct | 2,000,000 |
Reported balance
After 2024-02-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-02-13 · Grant · Acquired 2,000,000 · Balance 2,000,000 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F3: The option vested in two equal installments on July 1, 2022 and July 1, 2023. The remainder of the option vests on July 1, 2024. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.54 · Expires 2032-08-25 | Direct | 0 |
Reported balance
After 2024-02-13 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-02-13 · Disposition to issuer · Disposed 350,000 · Balance 0 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F4: One third of the option vested on August 25, 2023. The remainder of the option shall vest in two equal installments on August 25, 2024 and August 25, 2025. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2032-08-25 | Direct | 350,000 |
Reported balance
After 2024-02-13 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-02-13 · Grant · Acquired 350,000 · Balance 350,000 F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F4: One third of the option vested on August 25, 2023. The remainder of the option shall vest in two equal installments on August 25, 2024 and August 25, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested in three equal installments on February 28, 2019, February 28, 2020 and February 28, 2021.
F2: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options.
F3: The option vested in two equal installments on July 1, 2022 and July 1, 2023. The remainder of the option vests on July 1, 2024.
F4: One third of the option vested on August 25, 2023. The remainder of the option shall vest in two equal installments on August 25, 2024 and August 25, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2024 Filed Feb 16, 2024 14:06 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 350,000 | Not disclosed Strike: $1.92 | Not disclosed |
DisclosureSEC source: 0001731122-24-000263 · ownership.xml · derivative · entry 12 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-08-25 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F4 · derivative.exercise_date: One third of the option vested on August 25, 2023. The remainder of the option shall vest in two equal installments on August 25, 2024 and August 25, 2025. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:06 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | Disposition to issuerOption to Purchase Common Stock · Derivative | 350,000 | Not disclosed Strike: $2.54 | Not disclosed |
DisclosureSEC source: 0001731122-24-000263 · ownership.xml · derivative · entry 11 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 350,000 shares Expires 2032-08-25 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F4 · derivative.exercise_date: One third of the option vested on August 25, 2023. The remainder of the option shall vest in two equal installments on August 25, 2024 and August 25, 2025. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:06 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 2,000,000 | Not disclosed Strike: $1.92 | Not disclosed |
DisclosureSEC source: 0001731122-24-000263 · ownership.xml · derivative · entry 10 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 2,000,000 shares Expires 2031-07-19 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F3 · derivative.exercise_date: The option vested in two equal installments on July 1, 2022 and July 1, 2023. The remainder of the option vests on July 1, 2024. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:06 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,000,000 | Not disclosed Strike: $4.57 | Not disclosed |
DisclosureSEC source: 0001731122-24-000263 · ownership.xml · derivative · entry 9 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000,000 shares Expires 2031-07-19 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F3 · derivative.exercise_date: The option vested in two equal installments on July 1, 2022 and July 1, 2023. The remainder of the option vests on July 1, 2024. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:06 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 450,000 | Not disclosed Strike: $1.92 | Not disclosed |
DisclosureSEC source: 0001731122-24-000263 · ownership.xml · derivative · entry 8 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2031-06-11 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:06 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | Disposition to issuerOption to Purchase Common Stock · Derivative | 450,000 | Not disclosed Strike: $8.00 | Not disclosed |
DisclosureSEC source: 0001731122-24-000263 · ownership.xml · derivative · entry 7 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 450,000 shares Expires 2031-06-11 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:06 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 300,000 | Not disclosed Strike: $1.92 | Not disclosed |
DisclosureSEC source: 0001731122-24-000263 · ownership.xml · derivative · entry 6 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-11-21 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:06 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | Disposition to issuerOption to Purchase Common Stock · Derivative | 300,000 | Not disclosed Strike: $6.50 | Not disclosed |
DisclosureSEC source: 0001731122-24-000263 · ownership.xml · derivative · entry 5 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2028-11-21 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:06 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 5,226 | Not disclosed Strike: $1.92 | Not disclosed |
DisclosureSEC source: 0001731122-24-000263 · ownership.xml · derivative · entry 4 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,226 Underlying: Common Stock · 5,226 shares Expires 2028-09-19 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:06 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | Disposition to issuerOption to Purchase Common Stock · Derivative | 5,226 | Not disclosed Strike: $5.74 | Not disclosed |
DisclosureSEC source: 0001731122-24-000263 · ownership.xml · derivative · entry 3 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,226 shares Expires 2028-09-19 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:06 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 7,563 | Not disclosed Strike: $1.92 | Not disclosed |
DisclosureSEC source: 0001731122-24-000263 · ownership.xml · derivative · entry 2 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,563 Underlying: Common Stock · 7,563 shares Expires 2028-02-28 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 14:06 UTC | Lunai Bioworks Inc. RENB · Entity 7981 | Disposition to issuerOption to Purchase Common Stock · Derivative | 7,563 | Not disclosed Strike: $5.95 | Not disclosed |
DisclosureSEC source: 0001731122-24-000263 · ownership.xml · derivative · entry 1 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,563 shares Expires 2028-02-28 F2 · price: The transactions reported herein reflect a stock option repricing (the "Option Repricing") effective on February 13, 2024 (the "Repricing Date"). Pursuant to the Option Repricing, which was approved by stockholders on January 25, 2024, the exercise price of all repriced options has been amended to $1.92 per share, the closing price of the Company's common stock, par value $0.0001 per share (the "Common Stock"), on the date of the closing of the Registrant's acquisition of GEDi Cube Intl Ltd. There were no other changes to the terms of the options. F1 · derivative.exercise_date: The option vested in three equal installments on February 28, 2019, February 28, 2020 and February 28, 2021. Read SEC document |
| August 25, 2022 Filed Sep 15, 2022 16:36 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 350,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001731122-22-001581 · ownership.xml · derivative · entry 1 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common stock · 350,000 shares Expires 2032-08-25 F1 · derivative.exercise_date: The options vest ratably on August 25, 2023, August 25, 2024 and August 25, 2025. Read SEC document |
| July 19, 2021 Filed Jul 22, 2021 20:33 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to purchase shares of common stock · Derivative | 2,000,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001731122-21-001219 · ownership.xml · derivative · entry 1 Dybul Mark · CIK 0001734805 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common stock · 2,000,000 shares Expires 2031-07-19 F1 · derivative.exercise_date: The options vest ratably on July 1, 2022, July 1, 2023 and July 1, 2024. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 19:03 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | OtherCommon Stock | 180 | $0.00 | $0.00 |
DisclosureSEC source: 0001731122-20-001305 · ownership.xml · nonDerivative · entry 1 Dybul Mark · CIK 0001734805 · Director · Executive Vice Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,196 F1 · security: On December 14, 2020, Mark Dybul received 180 shares of common stock pursuant to a contractual right to receive shares upon the exercise of outstanding warrants of the Issuer. Read SEC document |
| June 11, 2020 Filed Jun 19, 2020 19:01 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 450,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001731122-20-000662 · ownership.xml · derivative · entry 1 Dybul Mark · CIK 0001734805 · Director · Executive Vice Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2030-06-11 Read SEC document |
| July 30, 2019 Filed Aug 2, 2019 01:28 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | OtherCommon Stock | 10,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001731122-19-000424 · ownership.xml · nonDerivative · entry 1 Dybul Mark · CIK 0001734805 · Director · Executive Vice Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,016 F1 · security: On July 30, 2019, Mark Dybul, M.D. received 10,680 shares of common stock pursuant to a contractual right to receive shares upon the exercise of warrants by warrant holders of the Issuer. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 02:44 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | OtherCommon Stock | 3,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001731122-19-000008 · ownership.xml · nonDerivative · entry 1 Dybul Mark · CIK 0001734805 · Director · Executive Vice Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,336 F1 · security: On December 31, 2018, Mark Dybul received 3,732 shares of common stock pursuant to a contractual right to receive shares upon the exercise of warrants by RS Bio ApS. Read SEC document |
| November 21, 2018 Filed Dec 7, 2018 18:46 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 300,000 | $6.50 Strike: $6.50 | $1,950,000.00 |
DisclosureSEC source: 0001731122-18-000180 · ownership.xml · derivative · entry 1 Dybul Mark · CIK 0001734805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,834 Underlying: Common Stock · 300,000 shares Expires 2018-11-21 Read SEC document |
| September 19, 2018 Filed Sep 27, 2018 17:04 UTC | Lunai Bioworks Inc. ENOB · Entity 7981 | GrantOption to Purchase Common Stock · Derivative | 5,226 | $5.74 Strike: $5.74 | $29,997.24 |
DisclosureSEC source: 0001731122-18-000087 · ownership.xml · derivative · entry 1 Dybul Mark · CIK 0001734805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,834 Underlying: Common Stock · 5,226 shares Expires 2028-09-19 F1 · security: On September 19, 2018, Dr. Dybul was granted an option to purchase shares of common stock of Enochian Biosciences, Inc. valued at $30,000, said option to vest on the anniversary date of Dr. Dybul's appointment as director of Enochian, exercisable at the closing market price per share on the date of the grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.